Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to acquire some of its assets for a total consideration of up to $10M.

HB-400 (NCT05770895) is currently being evaluated in a Phase 1 trial and is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma.

Gilead purchased 15 million shares and holds 19.4% stake in HOOKIPA. Equity investment is to advance the Gilead-partnered HIV program through Phase 1 trial expected to start in 1H of 2024.

Gilead is solely responsible for further development and commercialization of HB-400, referenced as GS-2829 and GS-6779. HOOKIPA earned a $5 million non-dilutive payment under its collaboration ...

Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the ...

Then Gilead on Thursday disclosed it bought 15 million shares of Austria-based HIV drug-development partner Hookipa Pharma Inc. (NASDAQ: HOOK) for $21.25 million, with Hookipa having an option to ...